Sugi Predict

Sugi Predict / Compounds / SCHEMBL330612

SCHEMBL330612

SCHEMBL330612

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](OC(=O)CCC(=O)O[C@H]5CC[C@@]6(C)C(=CC[C@H]7[C@@H]8CC[C@H]([C@H](C)CCCC(C)C)[C@@]8(C)CC[C@@H]76)C5)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.89

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ POLA1 P09884 1/20 0.77
▸ CYP46A1 Q9Y6A2 2/20 0.75
▸ OSBP P22059 3/20 0.71
▸ USP2 O75604 2/20 0.71
▸ LMNA P02545 1/20 0.71
▸ ABCB1 P08183 1/20 0.71
▸ RORC P51449 1/20 0.71
▸ OSBP2 Q969R2 1/20 0.71
▸ PLA2G2A P14555 1/20 0.66
▸ NPC1 O15118 1/20 0.64
▸ NR1H3 Q13133 5/20 0.63
▸ NPC1L1 Q9UHC9 2/20 0.61
▸ EPHA2 P29317 1/20 0.61
▸ CYP1A2 P05177 1/20 0.61
▸ GRIN1 Q05586 1/20 0.61
▸ GRIN2A Q12879 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26910780 1.00 POLA1 (0.77) POLA1CYP46A1OSBPUSP2LMNA
SCHEMBL14867494 0.97 POLA1 (0.76) POLA1CYP46A1OSBPUSP2LMNA
SCHEMBL3954236 0.97 POLA1 (0.76) POLA1CYP46A1OSBPUSP2LMNA
SCHEMBL3953210 0.97 POLA1 (0.76) POLA1CYP46A1OSBPUSP2LMNA
SCHEMBL24347041 0.97 POLA1 (0.78) POLA1CYP46A1OSBPUSP2LMNA
SCHEMBL23435048 0.97 POLA1 (0.78) POLA1CYP46A1OSBPUSP2LMNA
SCHEMBL20623479 0.97 POLA1 (0.78) POLA1CYP46A1OSBPUSP2LMNA
SCHEMBL23380104 0.97 POLA1 (0.78) POLA1CYP46A1OSBPUSP2LMNA
SCHEMBL20739412 0.97 POLA1 (0.78) POLA1CYP46A1OSBPUSP2LMNA
SCHEMBL20739369 0.97 POLA1 (0.78) POLA1CYP46A1OSBPUSP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1004 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122031421-A PH-sensitive cell membrane liposome fusion drug-loaded nanoparticle capable of targeted regulation of lung cancer immune microenvironment and preparation method and application thereof 上海交通大学医学院附属第九人民医院 2026-05-15 — — CN claimed
CN-122005778-A Herpes zoster vaccine containing novel adjuvant and preparation method thereof 江苏华诺泰生物医药科技有限公司 2026-05-12 — — CN claimed
US-20250186339-A1 COMPOSITION FOR INTRAORAL DELIVERY OF BIOLOGICALLY ACTIVE PEPTIDES AND PROTEINS SCHWARZ JOSEPH (CA) 2025-06-12 — — US claimed
CN-119959397-A Method for simultaneously detecting multiple cholesteric liquid crystal monomers in environmental medium 暨南大学 2025-05-09 — — CN claimed
CN-119792540-A Liposome with carrot glycoside or analogue thereof as membrane material, preparation method and application thereof 成都医学院 2025-04-11 — — CN claimed
CN-119499180-B Lipid multimeric complex, preparation method and application thereof in treating tumor bone metastasis 浙江大学 2025-04-11 — — CN claimed
CN-119735655-A Method for extracting membrane protein from VLPs preparation 武汉华美生物工程有限公司 2025-04-01 — — CN claimed
CN-119606927-A Gel emplastrum for treating arthralgia and preparation method thereof 杭州仁德药业股份有限公司 2025-03-14 — — CN claimed
CN-119591676-A Lipopeptide HIV membrane fusion inhibitor and pharmaceutical application 中国医学科学院病原生物学研究所 2025-03-11 — — CN claimed
CN-119499180-A Lipid multimeric complex, preparation method and application thereof in treating tumor bone metastasis 浙江大学 2025-02-25 — — CN claimed
CN-1679959-A Liver targeted auxiliary material containing D-glactose and sterol and its use SHENYANG MEDICAL SCIENCE UNIV (CN) 2005-10-12 — — CN claimed
US-20040156816-A1 Lipid-drug complexes in reversed liquid and liquid crystalline phases LYOTROPIC THERAPEUTICS, INC. 2004-08-12 — — US claimed
US-20040053993-A1 Compositions of tocol-soluble therapeutics SONUS PHARMACEUTICALS, INC. 2004-03-18 — — US claimed
WO-2004012680-A2 LIPID-DRUG COMPLEXES IN REVERSED LIQUID AND LIQUID CRYSTALLINE PHASES LYOTROPIC THERAPEUTICS, INC. (US) 2004-02-12 — — WO claimed
US-6479540-B1 Compositions of tocol-soluble therapeutics SONUS PHARMACEUTICALS, INC. 2002-11-12 — — US claimed
EP-1216026-A1 COMPOSITIONS OF TOCOL-SOLUBLE THERAPEUTICS SONUS PHARMACEUTICALS, INC. (US) 2002-06-26 — — EP claimed
WO-2001022937-A1 COMPOSITIONS OF TOCOL-SOLUBLE THERAPEUTICS SONUS PHARMACEUTICALS, INC. (US) 2001-04-05 — — WO claimed
US-5610180-A TOCOPHEROL AND CHOLESTEROL DERIVATIVES, CYTOPROTECTIVE AGENTS VIRGINIA COMMONWEALTH UNIVERSITY (US) 1997-03-11 — — US claimed
CN-1094410-A Hydroxy cholesterol succinic acid monoester and salt thereof SHENGYANG MEDICINE COLLEGE (CN) 1994-11-02 — — CN claimed
US-5198432-A Cytoprotective agents CENTER FOR INNOVATIVE TECHNOLOGY (US) 1993-03-30 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053993-A1 Compositions of tocol-soluble therapeutics TTPA, SLC25A13, PCTP POLA1 969/4885CYP46A1 1020/4885OSBP 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.